secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXICURE, INC. (XCUR)
CIK:        0001698530
Form:       8-K
Filed at:   2023-12-01T23:59:59+00:00
Accession:  0001698530-23-000123
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 4.02
LLM model:  deepseek-v4-flash:cloud@v2

Exicure restates Q1, Q2 2023; reclassifies ~$1.5M R&D expenses to G&A
---------------------------------------------------------------------

- Audit Committee determined it is no longer appropriate to record wind-down expenses as R&D; ~$0.6M in Q1 and ~$0.9M in Q2 reclassified to general and administrative.
- Net loss for affected periods unchanged; restated financial statements (10-Q/A) to be filed for Q1 and Q2 2023.
- Material weakness in internal control over financial reporting identified; disclosure controls ineffective.
- Company continues wind-down of biotech activities and exploration of strategic alternatives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1698530/000169853023000123/0001698530-23-000123-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1698530/000169853023000123/xcur-20231201.htm
  HTML page:      https://secwatch.observer/filing/0001698530-23-000123

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer